ASH 2015 | Obinutuzumab (GA101) plus bendamustine as front-line therapy in CLL
Véronique Leblond, MD, PhD from the Hospital of Pitié Salpêtrière, Paris, France, talks about one of the arms of the Phase IIIb GREEN clinical trial, of obinutuzumab (GA101) plus bendamustine in chronic lymphocytic leukemia (CLL) patients, presented at the American Society of Hematology (ASH) 2015 Annual Meeting. Patients in this arm had a complete remission rate of 40%, and the majority of them achieved minimum residual disease (MRD) negativity in the blood and approx. 50% were MRD negative in the bone marrow.
Get great new content delivered to your inboxSign up